Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

BACKGROUND: Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of the COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes. METHODS: Initial study of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovell, Jonathan F., Baik, Yeong Ok, Choi, Seuk Keun, Lee, Chankyu, Lee, Jeong-Yoon, Miura, Kazutoyo, Huang, Wei-Chiao, Park, Young-Shin, Woo, Sun-Je, Seo, Sang Hwan, Kim, Jae-Ouk, Song, Manki, Kim, Chung-Jong, Choi, Jae-Ki, Kim, Jieun, Choo, Eun Ju, Choi, Jung-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708508/
https://www.ncbi.nlm.nih.gov/pubmed/36447243
http://dx.doi.org/10.1186/s12916-022-02661-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708508/
https://www.ncbi.nlm.nih.gov/pubmed/36447243
http://dx.doi.org/10.1186/s12916-022-02661-1

Ejemplares similares